NCT07046780

A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 90 (estimated)
• Sponsor: PENG YUAN · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab Injection (QL1706). The primary objectives are to evaluate the safety and effectiveness of Iparomlimab and Tuvonralimab Injection (QL1706) in treating locally advanced or metastatic solid tumors.

Conditions

• Solid Tumor Cancer
• Metastatic Solid Tumors
• Locally Advanced

Interventions

Type	Name	Description
DRUG	Observation arm	To observe the efficacy and safety of Iparomilimab and Tuvonralimab in the treatment of patients with solid tumors in the real world

Timeline

• Start date: 2025-07-30
• Primary completion: 2027-07-30
• Completion: 2027-12-30
• First posted: 2025-07-02
• Last updated: 2025-07-02

Locations

1 site across 1 country: China